X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs SANOFI INDIA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE SANOFI INDIA CADILA HEALTHCARE/
SANOFI INDIA
 
P/E (TTM) x 31.7 33.6 94.3% View Chart
P/BV x 5.9 6.4 92.0% View Chart
Dividend Yield % 0.8 1.4 56.7%  

Financials

 CADILA HEALTHCARE   SANOFI INDIA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
SANOFI INDIA
Dec-16
CADILA HEALTHCARE/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs4604,560 10.1%   
Low Rs3054,400 6.9%   
Sales per share (Unadj.) Rs92.11,028.5 9.0%  
Earnings per share (Unadj.) Rs14.8129.0 11.5%  
Cash flow per share (Unadj.) Rs18.5186.0 9.9%  
Dividends per share (Unadj.) Rs3.2068.00 4.7%  
Dividend yield (eoy) %0.81.5 55.1%  
Book value per share (Unadj.) Rs68.0753.6 9.0%  
Shares outstanding (eoy) m1,023.7423.03 4,445.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.24.4 95.3%   
Avg P/E ratio x25.834.7 74.3%  
P/CF ratio (eoy) x20.724.1 85.9%  
Price / Book Value ratio x5.65.9 94.6%  
Dividend payout %21.652.7 41.0%   
Avg Mkt Cap Rs m391,581103,174 379.5%   
No. of employees `00016.93.6 465.2%   
Total wages/salary Rs m15,0023,592 417.7%   
Avg. sales/employee Rs Th5,594.56,537.7 85.6%   
Avg. wages/employee Rs Th890.1991.4 89.8%   
Avg. net profit/employee Rs Th899.9819.8 109.8%   
INCOME DATA
Net Sales Rs m94,29523,686 398.1%  
Other income Rs m1,286708 181.6%   
Total revenues Rs m95,58124,394 391.8%   
Gross profit Rs m19,0365,281 360.5%  
Depreciation Rs m3,7501,313 285.6%   
Interest Rs m45015 3,000.0%   
Profit before tax Rs m16,1224,661 345.9%   
Minority Interest Rs m3380-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,2891,691 76.2%   
Profit after tax Rs m15,1682,970 510.7%  
Gross profit margin %20.222.3 90.5%  
Effective tax rate %8.036.3 22.0%   
Net profit margin %16.112.5 128.3%  
BALANCE SHEET DATA
Current assets Rs m60,22315,673 384.2%   
Current liabilities Rs m53,0586,678 794.5%   
Net working cap to sales %7.638.0 20.0%  
Current ratio x1.12.3 48.4%  
Inventory Days Days7076 91.9%  
Debtors Days Days8822 395.1%  
Net fixed assets Rs m72,9848,098 901.3%   
Share capital Rs m1,024230 444.6%   
"Free" reserves Rs m68,57617,088 401.3%   
Net worth Rs m69,60017,356 401.0%   
Long term debt Rs m24,6840-   
Total assets Rs m152,20725,400 599.2%  
Interest coverage x36.8311.7 11.8%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.60.9 66.4%   
Return on assets %10.311.8 87.3%  
Return on equity %21.817.1 127.4%  
Return on capital %17.926.9 66.6%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m21,2807,145 297.8%   
Fx outflow Rs m10,8746,846 158.8%   
Net fx Rs m10,406299 3,480.3%   
CASH FLOW
From Operations Rs m13,4953,226 418.3%  
From Investments Rs m-29,103-1,555 1,871.6%  
From Financial Activity Rs m23,158-1,818 -1,273.8%  
Net Cashflow Rs m7,556-147 -5,140.1%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 8.3 14.4 57.6%  
FIIs % 5.9 14.6 40.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.5 104.8%  
Shareholders   44,069 15,184 290.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   DIVIS LABORATORIES  GLENMARK PHARMA  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 22, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS